Products
Latest Partnered Companies
Projects
Estimated Cost :
US$1.05 billion
AstraZeneca Invests US$1.05 billion (£1bn) to Construct New R&D Facility
AstraZeneca plans for the construction of state-of-the-art research and development (R&D) facility with an investment of US$1.05 billion (£1bn). The n...
Estimated Cost :
-
Rentschler Biopharma Plans to Open New Manufacturing Center in Boston
Rentschler Biopharma plans to open new manufacturing site that will be an extension
Estimated Cost :
-
Artiva Biotherapeutics to Construct New Research and Manufacturing Center in Republic of Korea
Artiva Biotherapeutics plans to construct new GMP manufacturing center. The facility will be an addition to the Artiva’s continued research and GMP ma...
Estimated Cost :
CHF 850 million
Lonza Constructs Two Next-Generation Mammalian Manufacturing Facilities
Lonza invests US$927 million (CHF850 million) to construct two next-generation mammalian manufacturing facilities
Press Release
Astellas Announces FDA Update on the FORTIS Clinical Trial of AT845 in Adults with Late-Onset Pompe Disease
Astellas Pharma Inc. announced that the US Food and Drug Administration (FDA) has placed a clinical hold on the FORTIS Phase 1/2 trial following the occurrence of a serious adverse event (SAE) of peripheral sensory neuropathy in one of the trial participants. FORTIS is a clinical trial evaluating AT845, an investigational adeno-associated virus (AAV) gene replacement therapy in adults with Late-Onset Pompe Disease.
AIkido Inc. Announces the Formation of a New Financial Services Subsidiary
AIkido Pharma Inc. announced the formation of a wholly owned subsidiary with the purpose of making strategic investments and acquisitions across the fintech and financial services industries. The new subsidiary is expected to be the centerpiece of a long-range plan to diversify AIkido's business beyond biotechnology, in order to reduce volatility and mitigate risk while increasing revenue and enhancing shareholder value.
Ixaka and Minaris Regenerative Medicine Sign Tech Transfer and GMP Manufacturing Agreement for Lead Cell Therapy Candidate REX-001
Ixaka Ltd, an integrated cell and gene therapy company, and Minaris Regenerative Medicine GmbH (“Minaris”), a leading contract development and manufacturing service provider for the cell and gene therapy industry, today announced that they have signed an agreement to enable technology transfer as well as clinical and commercial manufacture of REX-001, Ixaka’s lead autologous
Astellas Submits Fezolinetant New Drug Application to U.S. FDA
Astellas Pharma Inc. today announced a New Drug Application (NDA) for fezolinetant has been submitted to the U.S. Food and Drug Administration (FDA). Fezolinetant is an investigational oral, nonhormonal compound seeking approval for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause
Events
International Conference on Advances in Health and Medical Science (ICAHMS)
Articles
Top 12 Analytical Lab Equipments in Pharmaceutical Industry
The analytical lab equipments or instruments are used in analytical applications in pharmaceutical, food-processing laboratories
A Complete Guide on Blister Packaging Machine
Packaging machinery is one of the vital equipment in the pharmaceutical industry, food processing, and chemical
Nanotechnology in Drug Delivery to Eyes, Skin, and Wounds Via Topical Route
One of the most favored courses for administering medications to eyes, skin, and wounds is the topical route. The principle objective for this
An Overview - Active Pharmaceutical Ingredient (API)
Active Pharmaceutical Ingredient (API) is the term used to refer to the biologically active component of a drug product
Next-Generation Biological Therapeutics Discovery & Development
Focus on drug discovery and development has shifted away from small to large, complex molecular entities
Expert Talk
Testimonials
I have read it with interest. I think it could be of interest to managers and professionals in Asia's Pharma companies as well as global companies that wish to learn more about how to do business--from R&D to marketing-in Asia.
Baoping Wang - Research Director
Novo Nordisk (China) R&D Centre
Thank you for contacting us. One of our support staff will get in touch with you shortly.
Happy Surfing!
Regards,
Client Success Team (CRM),
